Clinical tolerance and toxicity of intravenous baclofen: A pilot study in a canine model

Linda E. Krach, Robert L. Kriel, Ned Patterson, Lisa A. Scherkenbach, Lisa D Coles, James C Cloyd

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: Assess safety and tolerance of intravenous (IV) baclofen using a dog model. Design: Prospective pharmacokinetic study involving 6 adult dogs. Two dogs received baclofen 10 mg oral and IV bolus doses. Subsequent 4 dogs were given IV boluses of 0.5, 1.0 and 1.5 mg/kg followed by constant infusion of baclofen (rates of 0.1, 0.2 and 0.4 mg/kg/hour). Also, dogs were given single IV 2 and 3 mg /kg bolus doses. Outcome measures included clinical observation scales and baclofen levels. Results: Oral bioavailability was 0.66 and 0.69 in 2 dogs. Following IV baclofen, terminal phase half-lives were 3.3 and 3.6 hours. Single bolus doses of 2 and 3 mg/kg caused mild to moderate clinical changes which were delayed at least 2 hours after peak blood levels. Boluses of 0.5 and 1.0 mg/kg with constant infusion between boluses were tolerated, however within 30 minutes of beginning constant infusion of 0.2 mg/kg/hr after the second bolus (1.0 mg/kg), dogs showed progressive sedation and ataxia. Clinical improvement occurred within 7 hours of stopping baclofen. Dogs appeared normal by the next morning. Conclusions: IV baclofen bolus doses of 0.5 to 3 mg/kg were well tolerated. Maximum clinical effect was delayed for at least 2 hours after peak plasma levels.

Original languageEnglish (US)
Pages (from-to)89-98
Number of pages10
JournalJournal of Pediatric Rehabilitation Medicine
Volume4
Issue number2
DOIs
StatePublished - Nov 7 2011

Fingerprint

Baclofen
Canidae
Dogs
Ataxia
Biological Availability
Pharmacokinetics
Observation
Outcome Assessment (Health Care)
Prospective Studies
Safety

Keywords

  • Baclofen
  • dogs
  • muscle spasticity
  • pharmacokinetic

Cite this

Clinical tolerance and toxicity of intravenous baclofen : A pilot study in a canine model. / Krach, Linda E.; Kriel, Robert L.; Patterson, Ned; Scherkenbach, Lisa A.; Coles, Lisa D; Cloyd, James C.

In: Journal of Pediatric Rehabilitation Medicine, Vol. 4, No. 2, 07.11.2011, p. 89-98.

Research output: Contribution to journalArticle

@article{167bf15c9d6b4a6fa5ef151a8faccb42,
title = "Clinical tolerance and toxicity of intravenous baclofen: A pilot study in a canine model",
abstract = "Objective: Assess safety and tolerance of intravenous (IV) baclofen using a dog model. Design: Prospective pharmacokinetic study involving 6 adult dogs. Two dogs received baclofen 10 mg oral and IV bolus doses. Subsequent 4 dogs were given IV boluses of 0.5, 1.0 and 1.5 mg/kg followed by constant infusion of baclofen (rates of 0.1, 0.2 and 0.4 mg/kg/hour). Also, dogs were given single IV 2 and 3 mg /kg bolus doses. Outcome measures included clinical observation scales and baclofen levels. Results: Oral bioavailability was 0.66 and 0.69 in 2 dogs. Following IV baclofen, terminal phase half-lives were 3.3 and 3.6 hours. Single bolus doses of 2 and 3 mg/kg caused mild to moderate clinical changes which were delayed at least 2 hours after peak blood levels. Boluses of 0.5 and 1.0 mg/kg with constant infusion between boluses were tolerated, however within 30 minutes of beginning constant infusion of 0.2 mg/kg/hr after the second bolus (1.0 mg/kg), dogs showed progressive sedation and ataxia. Clinical improvement occurred within 7 hours of stopping baclofen. Dogs appeared normal by the next morning. Conclusions: IV baclofen bolus doses of 0.5 to 3 mg/kg were well tolerated. Maximum clinical effect was delayed for at least 2 hours after peak plasma levels.",
keywords = "Baclofen, dogs, muscle spasticity, pharmacokinetic",
author = "Krach, {Linda E.} and Kriel, {Robert L.} and Ned Patterson and Scherkenbach, {Lisa A.} and Coles, {Lisa D} and Cloyd, {James C}",
year = "2011",
month = "11",
day = "7",
doi = "10.3233/PRM-2011-0160",
language = "English (US)",
volume = "4",
pages = "89--98",
journal = "Journal of Pediatric Rehabilitation Medicine",
issn = "1874-5393",
publisher = "IOS Press",
number = "2",

}

TY - JOUR

T1 - Clinical tolerance and toxicity of intravenous baclofen

T2 - A pilot study in a canine model

AU - Krach, Linda E.

AU - Kriel, Robert L.

AU - Patterson, Ned

AU - Scherkenbach, Lisa A.

AU - Coles, Lisa D

AU - Cloyd, James C

PY - 2011/11/7

Y1 - 2011/11/7

N2 - Objective: Assess safety and tolerance of intravenous (IV) baclofen using a dog model. Design: Prospective pharmacokinetic study involving 6 adult dogs. Two dogs received baclofen 10 mg oral and IV bolus doses. Subsequent 4 dogs were given IV boluses of 0.5, 1.0 and 1.5 mg/kg followed by constant infusion of baclofen (rates of 0.1, 0.2 and 0.4 mg/kg/hour). Also, dogs were given single IV 2 and 3 mg /kg bolus doses. Outcome measures included clinical observation scales and baclofen levels. Results: Oral bioavailability was 0.66 and 0.69 in 2 dogs. Following IV baclofen, terminal phase half-lives were 3.3 and 3.6 hours. Single bolus doses of 2 and 3 mg/kg caused mild to moderate clinical changes which were delayed at least 2 hours after peak blood levels. Boluses of 0.5 and 1.0 mg/kg with constant infusion between boluses were tolerated, however within 30 minutes of beginning constant infusion of 0.2 mg/kg/hr after the second bolus (1.0 mg/kg), dogs showed progressive sedation and ataxia. Clinical improvement occurred within 7 hours of stopping baclofen. Dogs appeared normal by the next morning. Conclusions: IV baclofen bolus doses of 0.5 to 3 mg/kg were well tolerated. Maximum clinical effect was delayed for at least 2 hours after peak plasma levels.

AB - Objective: Assess safety and tolerance of intravenous (IV) baclofen using a dog model. Design: Prospective pharmacokinetic study involving 6 adult dogs. Two dogs received baclofen 10 mg oral and IV bolus doses. Subsequent 4 dogs were given IV boluses of 0.5, 1.0 and 1.5 mg/kg followed by constant infusion of baclofen (rates of 0.1, 0.2 and 0.4 mg/kg/hour). Also, dogs were given single IV 2 and 3 mg /kg bolus doses. Outcome measures included clinical observation scales and baclofen levels. Results: Oral bioavailability was 0.66 and 0.69 in 2 dogs. Following IV baclofen, terminal phase half-lives were 3.3 and 3.6 hours. Single bolus doses of 2 and 3 mg/kg caused mild to moderate clinical changes which were delayed at least 2 hours after peak blood levels. Boluses of 0.5 and 1.0 mg/kg with constant infusion between boluses were tolerated, however within 30 minutes of beginning constant infusion of 0.2 mg/kg/hr after the second bolus (1.0 mg/kg), dogs showed progressive sedation and ataxia. Clinical improvement occurred within 7 hours of stopping baclofen. Dogs appeared normal by the next morning. Conclusions: IV baclofen bolus doses of 0.5 to 3 mg/kg were well tolerated. Maximum clinical effect was delayed for at least 2 hours after peak plasma levels.

KW - Baclofen

KW - dogs

KW - muscle spasticity

KW - pharmacokinetic

UR - http://www.scopus.com/inward/record.url?scp=80155153043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80155153043&partnerID=8YFLogxK

U2 - 10.3233/PRM-2011-0160

DO - 10.3233/PRM-2011-0160

M3 - Article

C2 - 21955965

AN - SCOPUS:80155153043

VL - 4

SP - 89

EP - 98

JO - Journal of Pediatric Rehabilitation Medicine

JF - Journal of Pediatric Rehabilitation Medicine

SN - 1874-5393

IS - 2

ER -